Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics

Verve Therapeutics Inc  (NASDAQ: VERV ) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc  (NASDAQ: BEAM ), which amended the agreement initially announced in April 2019. The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets. Under the amendment, ... Full story available on Benzinga.com